Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Parrish

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
The Lancet. Haematology|September 9, 2024
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trialGordon Cook, A John Ashcroft, Ethan Senior, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 18, 2020
Conducting an Oral Food Challenge: An Update to the 2009 Adverse Reactions to Foods Committee Work Group ReportJ Andrew Bird, Stephanie Leonard, Marion Groetch, et al.
The Lancet. Haematology|July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, A John Ashcroft, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
British Journal of Haematology|February 23, 2023
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysisAnnabel McMillan, Supratik Basu, Kamaraj Karunanithi, et al.
Leukemia Research|November 13, 2024
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experienceGiovanna Lucchini, Elena Cozma, Aimee Jackson, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
British Journal of Haematology|February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.
British Journal of Haematology|February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Journal for Immunotherapy of Cancer|July 3, 2019
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21Louise M E Müller, Matthew Holmes, Joanne L Michael, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
The Lancet. Haematology|September 9, 2024
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trialGordon Cook, A John Ashcroft, Ethan Senior, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 18, 2020
Conducting an Oral Food Challenge: An Update to the 2009 Adverse Reactions to Foods Committee Work Group ReportJ Andrew Bird, Stephanie Leonard, Marion Groetch, et al.
The Lancet. Haematology|July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, A John Ashcroft, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
British Journal of Haematology|February 23, 2023
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysisAnnabel McMillan, Supratik Basu, Kamaraj Karunanithi, et al.
Leukemia Research|November 13, 2024
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experienceGiovanna Lucchini, Elena Cozma, Aimee Jackson, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
British Journal of Haematology|February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.
British Journal of Haematology|February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Journal for Immunotherapy of Cancer|July 3, 2019
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21Louise M E Müller, Matthew Holmes, Joanne L Michael, et al.
Pageof 6